Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation (Q33555894)

28 July 2017

1 reference

title

Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation (English)

1 reference

28 July 2017

0 references

Or Kakhlon

1 reference

28 July 2017

William Breuer

series ordinal

1 reference

28 July 2017

Z Ioav Cabantchik

series ordinal

1 reference

28 July 2017

publication date

1 March 2010

1 reference

Canadian Journal of Physiology and Pharmacology

28 July 2017

published in

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

187-196

1 reference

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

28 July 2017

cites work

1 reference

Metals in Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities

21 January 2018

1 reference

Selective iron chelation in Friedreich ataxia: biologic and clinical implications

21 January 2018

1 reference

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy

21 January 2018

1 reference

Intracellular labile iron.

21 January 2018

1 reference

Therapeutics for Alzheimer's disease based on the metal hypothesis

21 January 2018

1 reference

Recent advances in the understanding of inherited sideroblastic anaemia

21 January 2018

1 reference

The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.

21 January 2018

1 reference

The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast

21 January 2018

1 reference

Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia

21 January 2018

1 reference

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

21 January 2018

1 reference

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

21 January 2018

1 reference

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

21 January 2018

1 reference

Fluorescence analysis of the labile iron pool of mammalian cells.

21 January 2018

1 reference

Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)

21 January 2018

1 reference

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation.

21 January 2018

1 reference

Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity

21 January 2018

1 reference

Molecular pathogenesis of anemia of chronic disease

21 January 2018

1 reference

Molecular control of iron transport

21 January 2018

1 reference

Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells

21 January 2018

1 reference

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences

21 January 2018

1 reference

Imaging iron stores in the brain using magnetic resonance imaging

21 January 2018

1 reference

Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability

21 January 2018

1 reference

Deficiency of skeletal muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human muscle oxidative defect

21 January 2018

1 reference

Neurodegeneration with brain iron accumulation: from genes to pathogenesis

21 January 2018

1 reference

Purging iron from the heart.

21 January 2018

1 reference

Objectives and mechanism of iron chelation therapy

21 January 2018

1 reference

The labile iron pool: characterization, measurement, and participation in cellular processes(1).

21 January 2018

1 reference

Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation

21 January 2018

1 reference

New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review

21 January 2018

1 reference

Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia

21 January 2018

1 reference

Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases

21 January 2018

1 reference

Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.

21 January 2018

1 reference

Endoplasmic reticulum stress involved in heart and liver injury in iron-loaded rats

21 January 2018

1 reference

Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

21 January 2018

1 reference

Intramuscular desferrioxamine in patients with Alzheimer's disease

21 January 2018

1 reference

Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance

21 January 2018

1 reference

Metals ions and neurodegeneration

21 January 2018

1 reference

Iron trafficking in the mitochondrion: novel pathways revealed by disease.

21 January 2018

1 reference

Friedreich ataxia: the clinical picture

21 January 2018

1 reference

The pathogenesis of Friedreich ataxia and the structure and function of frataxin

21 January 2018

1 reference

The chelatable iron pool in living cells: a methodically defined quantity

21 January 2018

1 reference

Concepts and goals in the management of transfusional iron overload.

21 January 2018

1 reference

Multicellular models of Friedreich ataxia.

21 January 2018

1 reference

Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits

21 January 2018

1 reference

Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.

21 January 2018

1 reference

Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron

21 January 2018

1 reference

Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences.

21 January 2018

1 reference

Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia

21 January 2018

1 reference

Iron-sulfur cluster biogenesis and human disease

21 January 2018

1 reference

Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture

21 January 2018

1 reference

Reversed siderophores act as antimalarial agents

21 January 2018

1 reference

A cytosolic iron chaperone that delivers iron to ferritin.

21 January 2018

1 reference

Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia

21 January 2018

1 reference

Therapeutic iron chelators and their potential side-effects

21 January 2018

1 reference

Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation

21 January 2018

1 reference

Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications

21 January 2018

1 reference

Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression

21 January 2018

1 reference

ER stress controls iron metabolism through induction of hepcidin

21 January 2018

1 reference

Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis

21 January 2018

1 reference

Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo

21 January 2018

1 reference

Increased iron in the dentate nucleus of patients with Friedrich's ataxia

21 January 2018

1 reference

Modification of iron regulation by the inflammatory response.

21 January 2018

1 reference

Iron metabolism in the anemia of chronic disease.

21 January 2018

1 reference

Anemia of chronic disease.

21 January 2018

1 reference

The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation

21 January 2018

1 reference

Iron dysregulation in Friedreich ataxia

21 January 2018

1 reference

The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis

21 January 2018

1 reference

Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus

21 January 2018

1 reference

The effects of frataxin silencing in HeLa cells are rescued by the expression of human mitochondrial ferritin

21 January 2018

1 reference

A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome

21 January 2018

1 reference

Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration

21 January 2018

1 reference

The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction†

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1139/Y09-128

1 reference

28 July 2017

1 reference